Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration-Approved Anticancer Drugs: A Call for Systematic Data Availability

被引：0

作者：

Modi, Natansh D. ^{[1
]}

Swain, Sandra M. ^{[2
]}

Buyse, Marc ^{[3
,4
]}

Kuderer, Nicole M. ^{[5
]}

Rowland, Andrew ^{[1
]}

Rockhold, Frank W. ^{[6
]}

Sorich, Michael J. ^{[1
]}

Hopkins, Ashley M. ^{[1
]}

机构：

[1] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, Australia

[2] MedStar Hlth, Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA

[3] Hasselt Univ, Int Drug Dev Inst IDDI, Hasselt, Belgium

[4] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat, Hasselt, Belgium

[5] Adv Canc Res Grp, Kirkland, WA USA

[6] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 32期

基金：

英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;

关键词：

D O I：

10.1200/JCO.24.00539

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：6

共 50 条

[21] A Mixture of US Food and Drug Administration-Approved Monoaminergic Drugs Protects the Retina From Light Damage in Diverse Models of Night Blindness
Leinonen, Henri
Choi, Elliot H.
Gardella, Anthony
Kefalov, Vladimir J.
Palczewski, Krzysztof
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (05) : 1442 - 1453
[22] Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
Kakadia, Sunilkumar
Yarlagadda, Naveen
Awad, Ramez
Kundranda, Madappa
Niu, Jiaxin
Naraev, Boris
Mina, Lida
Dragovich, Tomislav
Gimbel, Mark
Mahmoud, Fade
ONCOTARGETS AND THERAPY, 2018, 11 : 7095 - 7107
[23] Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized Study
Mross, Klaus
STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 (07) : 407 - 408
[24] Ethical considerations in design of a study to evaluate a US Food and Drug Administration-approved indication: Antivenom versus placebo for copperhead envenomation
Gerardo, Charles J.
Lavonas, Eric J.
McKinney, Ross E.
CLINICAL TRIALS, 2014, 11 (05) : 560 - 564
[25] Strong Pharmacokinetic Drug-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2021: Mechanisms and Clinical Implications
Yu, Jingjing
Wang, Yan
Ragueneau-Majlessi, Isabelle
CLINICAL THERAPEUTICS, 2022, 44 (11) : 1536 - 1544
[26] Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2020: Mechanistic Understanding and Clinical RecommendationsS
Yu, Jingjing
Wang, Yan
Ragueneau-Majlessi, Isabelle
DRUG METABOLISM AND DISPOSITION, 2022, 50 (01) : 1 - 7
[27] Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis
Naci, Huseyin
Zhang, Yichen
Woloshin, Steven
Guan, Xiaodong
Xu, Ziyue
Wagner, Anita K.
LANCET ONCOLOGY, 2024, 25 (06): : 760 - 769
[28] Ten-year Core Study Data for Sientra's Food and Drug Administration-Approved Round and Shaped Breast Implants with Cohesive Silicone Gel
Stevens, W. Grant
Calobrace, M. Bradley
Alizadeh, Kaveh
Zeidler, Kamakshi R.
Harrington, Jennifer L.
d'Incelli, Rosalyn C.
PLASTIC AND RECONSTRUCTIVE SURGERY, 2018, 141 : 7S - 19S
[29] Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2017
Yu, Jingjing
Petrie, Ichiko D.
Levy, Rene H.
Ragueneau-Majlessi, Isabelle
DRUG METABOLISM AND DISPOSITION, 2019, 47 (02) : 135 - 144
[30] Inadequate and delayed characterization of cutaneous reactions for US Food and Drug Administration-approved oncologic drugs from 2011-2020 leading to medication discontinuation
Yang, Jason J.
So, Naomi
Maloney, Nolan J.
Arzeno, Julia
Clifton, Katherine K.
Bach, Daniel Q.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (05) : 1351 - 1352

← 1 2 3 4 5 →